Recent advances in animal models of systemic sclerosis

Journal of Dermatology

Volumn 43, Issue 1, 2016, Pages 19-28

  Asano, Yoshihide ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fli1+ mice; Fra2 transgenic mice; Klf5 + ; new genetic animal models; systemic sclerosis; urokinase type plasminogen activator receptor deficient mice

Indexed keywords

BETA CATENIN; BLOOM SYNDROME HELICASE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; HLA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; KRUPPEL LIKE FACTOR 5; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR FRA 2; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; FLI1 PROTEIN, MOUSE; FOSL2 PROTEIN, MOUSE; KLF5 PROTEIN, MOUSE; KRUPPEL LIKE FACTOR; PLAUR PROTEIN, MOUSE; UROKINASE RECEPTOR;

ANIMAL MODEL; CAPILLARY ENDOTHELIAL CELL; CRE ER MOUSE; DNA METHYLATION; DOWN REGULATION; ENVIRONMENTAL FACTOR; EPIGENETIC REPRESSION; FRA2 TRANSGENIC MOUSE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; HAPLOINSUFFICIENCY; HETEROZYGOSITY; HUMAN; IMMUNE RESPONSE; INTERSTITIAL LUNG DISEASE; KLF5 FLI1 MOUSE; LYMPHOCYTIC INFILTRATION; MOLECULAR PATHOLOGY; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PULMONARY VASCULAR DISEASE; REVIEW; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TBRIIDK MOUSE; TSK 1 MOUSE; UPREGULATION; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR DEFICIENT MOUSE; ANIMAL; DEFICIENCY; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; MOUSE; SCLERODERMA, SYSTEMIC; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; FOS-RELATED ANTIGEN-2; HAPLOINSUFFICIENCY; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEIN C-FLI-1; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SCLERODERMA, SYSTEMIC;

EID: 84962424898     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13185     Document Type: Review

References (109)

1. Abraham DJ, Krieg T, Distler J, Distler O,. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48 (Suppl 3): iii3-iii7.
2. Asano Y, Sato S,. Vasculopathy in scleroderma. Semin Immunopathol 2015; 37: 489-500.
3. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R,. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36: 598-606.
4. Tourkina E, Bonner M, Oates J, et al,. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011; 4: 15.
5. Nikitorowicz-Buniak J, Denton CP, Abraham D, Stratton R,. Partially evoked epithelial-mesenchymal transition (EMT) is associated with increased TGFβ signaling within lesional scleroderma skin. PLoS ONE 2015; 10: e0134092.
6. Jimenez SA,. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol 2013; 2013: 835948.
7. Scharffetter K, Lankat-Buttgereit B, Krieg T,. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988; 18: 9-17.
8. Gruschwitz M, Müller PU, Sepp N, Hofer E, Fontana A, Wick G,. Transcription and expression of transforming growth factor type β in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990; 94: 197-203.
9. Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg S,. Expression of TGF- β1,-β2 and-β3 in localized and systemic scleroderma. J Dermatol Sci 1999; 21: 13-22.
10. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T,. Co-localization of transforming growth factor β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990; 86: 917-922.
11. Bhattacharyya S, Kelley K, Melichian DS, et al,. Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013; 182: 192-205.
12. Bhattacharyya S, Tamaki Z, Wang W, et al,. FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 2014; 6: 232ra50.
13. Takahashi T, Asano Y, Ichimura Y, et al,. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheumatol 2015; 67: 254-265.
14. Bhattacharyya S, Varga J,. Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis. Curr Rheumatol Rep 2015; 17: 474.
15. Yamamoto T,. Animal model of systemic sclerosis. J Dermatol 2010; 37: 26-41.
16. Beyer C, Schett G, Distler O, Distler JH,. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010; 62: 2831-2844.
17. Asano Y, Sato S,. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep 2013; 15: 382.
18. Servettaz A, Goulvestre C, Kavian N, et al,. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 2009; 182: 5855-5864.
19. Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S,. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011; 63: 3575-3585.
20. Stawski L, Han R, Bujor AM, Trojanowska M,. Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther 2012; 14: R194.
21. Siracusa LD, McGrath R, Ma Q, et al,. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996; 6: 300-313.
22. Menton DN, Hess RA,. The ultrastructure of collagen in the dermis of tight-skin (Tsk) mutant mice. J Invest Dermatol 1980; 74: 139-147.
23. Bocchieri MH, Henriksen PD, Kasturi KN, Muryoi T, Bona CA, Jimenez SA,. Evidence for autoimmunity in the tight skin mouse model of systemic sclerosis. Arthritis Rheum 1991; 34: 599-605.
24. Szapiel SV, Fulmer JD, Hunninghake GW, et al,. Hereditary emphysema in the tight-skin (Tsk/+) mouse. Am Rev Respir Dis 1981; 123: 680-685.
25. Sonnylal S, Denton CP, Zheng B, et al,. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007; 56: 334-344.
26. Denton CP, Zheng B, Evans LA, et al,. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003; 278: 25109-25119.
27. Pannu J, Gore-Hyer E, Yamanaka M, et al,. An increased transforming growth factor β receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis Rheum 2004; 50: 1566-1577.
28. Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M,. Increased levels of transforming growth factor β receptor type I and up-regulation of matrix gene program: A model of scleroderma. Arthritis Rheum 2006; 54: 3011-3021.
29. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M,. Transforming growth factor-β receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 2007; 282: 10405-10413.
30. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K,. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-264.
31. Asano Y, Ihn H, Jinnin M, Tamaki K, Sato S,. Altered dynamics of transforming growth factor β(TGF-β) receptors in scleroderma fibroblasts. Ann Rheum Dis 2011; 70: 384-387.
32. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL,. Distinct endocytic pathways regulate TGF-β receptor signalling and turnover. Nat Cell Biol 2003; 5: 410-421.
33. Drab M, Verkade P, Elger M, et al,. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293: 2449-2452.
34. Zhao YY, Liu Y, Stan RV, et al,. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 2002; 99: 11375-11380.
35. Del Galdo F, Sotgia F, de Almeida CJ, et al,. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58: 2854-2865.
36. Sonnylal S, Shi-Wen X, Leoni P, et al,. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum 2010; 62: 1523-1532.
37. Varga J, Whitfield ML,. Transforming growth factor-β in systemic sclerosis (scleroderma). Front Biosci (Schol Ed) 2009; 1: 226-235.
38. Wei J, Melichian D, Komura K, et al,. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 2011; 63: 1707-1717.
39. Beyer C, Schramm A, Akhmetshina A, et al,. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012; 71: 761-767.
40. Gershwin ME, Abplanalp H, Castles JJ, et al,. Characterization of a spontaneous disease of white leghorn chickens resembling progressive systemic sclerosis (scleroderma). J Exp Med 1981; 153: 1640-1659.
41. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G,. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-792.
42. Eferl R, Hasselblatt P, Rath M, et al,. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA 2008; 105: 10525-10530.
43. Maurer B, Busch N, Jüngel A, et al,. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation 2009; 120: 2367-2376.
44. Reich N, Maurer B, Akhmetshina A, et al,. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010; 62: 280-290.
45. Maurer B, Reich N, Juengel A, et al,. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012; 71: 1382-1387.
46. Venalis P, Kumánovics G, Schulze-Koops H, et al,. Cardiomyopathy in murine models of systemic sclerosis. Arthritis Rheumatol 2015; 67: 508-516.
47. Manetti M, Rosa I, Milia AF, et al,. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 2014; 73: 1700-1709.
48. Manetti M, Rosa I, Fazi M, et al,. Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice. Ann Rheum Dis 2015; doi: 10.1136/annrheumdis-2015-207803.
49. Noda S, Asano Y, Nishimura S, et al,. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 2014; 5: 5797.
50. Asano Y,. Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features. Med Mol Morphol 2015; 48: 123-128.
51. ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S,. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009; 98: 265-267.
52. Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R,. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010; 51: 272-276.
53. Blasi F, Carmeliet P,. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
54. Kanno Y, Kaneiwa A, Minamida M, et al,. The absence of uPAR is associated with the progression of dermal fibrosis. J Invest Dermatol 2008; 128: 2792-2797.
55. Bernstein AM, Twining SS, Warejcka DJ, Tall E, Masur SK,. Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol Biol Cell 2007; 18: 2716-2727.
56. D'Alessio S, Fibbi G, Cinelli M, et al,. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004; 50: 3275-3285.
57. Margheri F, Manetti M, Serratì S, et al,. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 2006; 54: 3926-3938.
58. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD,. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001; 44: 1359-1362.
59. Feghali-Bostwick C, Medsger TA, Wright TM,. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 1956-1963.
60. Broen JC, Radstake TR, Rossato M,. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 2014; 10: 671-681.
61. Wang Y, Fan PS, Kahaleh B,. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-2279.
62. Wang Y, Kahaleh B,. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med 2013; 17: 1291-1299.
63. Hu B, Gharaee-Kermani M, Wu Z, Phan SH,. Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis. Am J Pathol 2011; 178: 1500-1508.
64. Lian X, Xiao R, Hu X, et al,. DNA demethylation of CD40 l in CD4 + T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum 2012; 64: 2338-2345.
65. Jiang H, Xiao R, Lian X, et al,. Demethylation of TNFSF7 contributes to CD70 overexpression in CD4 + T cells from patients with systemic sclerosis. Clin Immunol 2012; 143: 39-44.
66. Wang Y, Shu Y, Xiao Y, et al,. Hypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis. Clin Epigenetics 2014; 6: 25.
67. Altorok N, Tsou PS, Coit P, Khanna D, Sawalha AH,. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann Rheum Dis 2015; 74: 1612-1620.
68. Ben-David Y, Giddens EB, Bernstein A,. Identification and mapping of a common proviral integration site Fli-1 in erythroleukemia cells induced by Friend murine leukemia virus. Proc Natl Acad Sci USA 1990; 87: 1332-1336.
69. Ben-David Y, Giddens EB, Letwin K, Bernstein A,. Erythroleukemia induction by Friend murine leukemia virus: insertional activation of a new member of the ets gene family, Fli-1, closely linked to c-ets-1. Genes Dev 1991; 5: 908-918.
70. Delattre O, Zucman J, Plougastel B, et al,. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-165.
71. Hollenhorst PC, Jones DA, Graves BJ,. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 2004; 32: 5693-5702.
72. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M,. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001; 276: 20839-20848.
73. Kubo M, Czuwara-Ladykowska J, Moussa O, et al,. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163: 571-581.
74. Spyropoulos DD, Pharr PN, Lavenburg KR, et al,. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 2000; 20: 5643-5652.
75. Masuya M, Moussa O, Abe T, et al,. Dysregulation of granulocyte, erythrocyte, and NK cell lineages in Fli-1 gene-targeted mice. Blood 2005; 105: 95-102.
76. Asano Y, Czuwara J, Trojanowska M,. Transforming growth factor-β regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007; 282: 34672-34683.
77. Asano Y, Trojanowska M,. Phosphorylation of Fli1 at threonine 312 by protein kinase C δ promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor β. Mol Cell Biol 2009; 29: 1882-1894.
78. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M,. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009; 29: 425-434.
79. Asano Y, Stawski L, Hant F, et al,. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-1998.
80. Shirasaki F, Makhluf HA, LeRoy C, Watson DK, Trojanowska M,. Ets transcription factors cooperate with Sp1 to activate the human tenascin-C promoter. Oncogene 1999; 18: 7755-7764.
81. Dong JT, Chen C,. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 2009; 66: 2691-2706.
82. Takeda N, Manabe I, Uchino Y, et al,. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010; 120: 254-265.
83. Fujiu K, Manabe I, Nagai R,. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J Clin Invest 2011; 121: 3425-3441.
84. Whitfield ML, Finlay DR, Murray JI, et al,. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100: 12319-12324.
85. Taniguchi T, Asano Y, Akamata K, et al,. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated fli-1-haploinsufficient mice. Arthritis Rheumatol 2015; 67: 517-526.
86. Noda S, Asano Y, Akamata K, et al,. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS ONE 2012; 7: e32272.
87. Noda S, Asano Y, Takahashi T, et al,. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 2013; 52: 790-799.
88. Ichimura Y, Asano Y, Akamata K, et al,. Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res 2014; 306: 331-338.
89. Saigusa R, Asano Y, Taniguchi T, et al,. A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis. Exp Dermatol 2015; 24: 127-132.
90. Akamata K, Asano Y, Taniguchi T, et al,. Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. Rheumatology (Oxford) 2015; 54: 1308-1316.
91. Takahashi T, Asano Y, Noda S, et al,. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement, and renal dysfunction in systemic sclerosis. Br J Dermatol 2015; 173: 681-689.
92. Dong C, Zhu S, Wang T, et al,. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99: 3908-3913.
93. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K,. Increased expression levels of integrin αVβ5 on scleroderma fibroblasts. Am J Pathol 2004; 164: 1275-1292.
94. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K,. Increased expression of integrin αVβ3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J Immunol 2005; 175: 7708-7718.
95. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K,. Involvement of αVβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005; 52: 2897-2905.
96. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K,. Increased expression of integrin αVβ5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006; 168: 499-510.
97. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S,. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-284.
98. Murata M, Fujimoto M, Matsushita T, et al,. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008; 50: 240-242.
99. Chizzolini C,. T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 1999; 21: 431-450.
100. Nakashima T, Jinnin M, Yamane K, et al,. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012; 188: 3573-3583.
101. Yoshizaki A, Yanaba K, Iwata Y, et al,. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010; 185: 2502-2515.
102. Higashi-Kuwata N, Jinnin M, Makino T, et al,. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010; 12: R128.
103. Varga J, Pasche B,. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-206.
104. Fujimoto M, Sato S,. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005; 17: 746-751.
105. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E,. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007; 56: 3167-3168.
106. Khan K, Xu S, Nihtyanova S, et al,. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012; 71: 1235-1242.
107. Giacomelli R, Cipriani P, Danese C, et al,. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor β1. J Rheumatol 1996; 23: 291-296.
108. Jordan S, Distler JH, Maurer B, et al,., Group obotERs. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74: 1188-1194.
109. Sumida H, Asano Y, Tamaki Z, et al,. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 2014; 41: 418-420.